RVMD Earnings Date: Nov 4, 2026 (Estimated) — Revolution Medicines, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is RVMD's next earnings date?
Revolution Medicines, Inc. (RVMD) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$2.35 on revenue of $25.6M.
How did RVMD do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Revolution Medicines, Inc. posted EPS of -$3.06 versus the -$2.04 estimate, a miss of 52.2%. Revenue was $0 against a $1.8M estimate. The stock's 1-day post-earnings move was +0.3%.
How much does RVMD stock move after earnings?
RVMD beat EPS estimates in 0 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.5% (up or down) in the day after earnings.
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -2.04 | -3.06 | -52.24% | $0 | ❌ Miss | +0.26% | +4.03% | +6.88% |
| 2026-05-06 | Q1 2026 | -1.84 | -2.29 | -24.46% | $0 | ❌ Miss | -5.67% | -0.75% | -1.22% |
| 2026-02-25 | Q4 2025 | -1.56 | -1.86 | -19.23% | $0 | ❌ Miss | -1.06% | -1.99% | -9.72% |
| 2025-11-05 | Q3 2025 | -1.40 | -1.61 | -15.00% | $0 | ❌ Miss | +3.44% | +10.94% | +34.21% |
| 2025-08-06 | Q2 2025 | -1.05 | -1.31 | -24.76% | $0 | ❌ Miss | -4.69% | -1.64% | +10.44% |
| 2025-02-26 | Q4 2024 | -0.96 | -1.12 | -16.67% | $0 | ❌ Miss | -3.51% | -2.17% | -5.93% |
| 2024-11-06 | Q3 2024 | 0.87 | -0.94 | -208.05% | $0 | ❌ Miss | -0.54% | -2.17% | -19.10% |
| 2024-08-07 | Q2 2024 | -0.77 | -0.81 | -5.19% | $0 | ❌ Miss | -0.69% | +0.73% | -1.02% |
Showing last 8 quarters.